MetricSide LogoMetricSide
Learn
  1. Home
  2. Companies
  3. Healthcare
  4. ALGN
OverviewMetricsPricesRevenue & ProfitAssets & LiabilitiesCash FlowMarginsPrice RatiosOthers
MetricSide

Standardized stock fundamentals and valuation metrics. Analyze revenue, EBITDA, free cash flow, and more with interactive charts.

Stock Sectors

  • Technology
  • Healthcare
  • Financials
  • Consumer
  • Industrials
  • Energy
  • Real Estate
  • Materials

Legal & Contact

  • Terms of Service
  • Privacy Policy
  • Contact Us
Not Financial Advice: MetricSide is a data aggregation and visualization tool. Nothing on this website constitutes investment advice, a recommendation, or a solicitation to buy or sell any security. All data is provided for informational and educational purposes only. Past performance is not indicative of future results. Always consult a qualified financial professional before making investment decisions. Data accuracy is not guaranteed — verify critical information against official sources.

© 2026 MetricSide. All rights reserved.

Align Technology (ALGN) Stock Fundamentals, Analysis & Risk Signals

Health score, competitive moat, risk signals, and key metrics at a glance.

NasdaqGS•Healthcare•Medical Instruments & Supplies
B
GoodMetricSide Score: 68/100
ProfitabilityProfit20/30
GrowthGrowth15/25
Balance SheetBalance17/25
Cash QualityCash16/20
Price & Volume
Market Cap $13.18B

Align Technology, Inc. provides Invisalign clear aligners, Vivera retainers, and iTero intraoral scanners and services in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers Invisalign comprehensive package to treat adults and teens malocclusion and features, and orthodontic needs of teenage or younger patients; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients between the ages of six and ten years with a mixture of primary/baby and permanent teeth. This segment also provides Invisalign express, Invisalign lite, and Invisalign moderate; Invisalign Go, Invisalign Go express, and Invisalign Go Plus; retention products, Invisalign training, adjusting tools used by dental professionals during treatment, ancillary Invisalign accessory products, and other oral health products; Invisalign Professional Whitening system; Invisalign Palatal Expander, a 3D printed orthodontic device; and 3D printing solutions. Its Imaging Systems and CAD/CAM Services segment offers iTero intraoral scanning system, a single hardware platform for restorative or orthodontic procedures; exocad, a computer-aided design and computer-aided manufacturing software; orthodontist software for digital records storage, orthodontic diagnosis, and fabrication of printed models and retainers; and restorative software for general practitioner dentists, prosthodontists, periodontists, and oral surgeons. This segment also offers Invisalign outcome simulator, a chair-side and cloud-based application for the iTero scanner; Invisalign progress assessment tool; Align Oral Health Suite, a digital interface for dental consultations; iTero TimeLapse technology for doctors or practitioners to compare a patient's historic 3D scans to the present-day scan; and subscription software, disposables, rents scanners, and pay per scan services. Align Technology, Inc. was incorporated in 1997 and is headquartered in Tempe, Arizona.

Moat Signals

Competitive analysis based on 64 quarters of fundamental data

Pricing Power

Moderate Moat

Operating margins are positive at ~14.1% on average, but show some variability — pricing power may be sensitive to market conditions.

Competitive Advantage

Moderate Moat

ROE is positive at ~10.8% on average, adequate but below the threshold typically associated with wide moats.

Cash Generation

Moderate Moat

8 of the last 8 quarters generated positive FCF. The company generally funds itself but has occasional cash consumption quarters.

Demand Durability

Moderate Moat

Revenue shows resilience with 5 of 7 quarters posting growth — demand is generally stable but has seen some soft patches.

Risk Signals

Data-driven red flags and warnings across 64 quarters

Low Risk

Margin Pressure

Watch

Operating margins declined 7.7% — watch for continued compression, which may signal competitive or cost pressure.

Earnings Quality

Healthy

FCF covers net income by 1.5x on average — earnings are well-supported by cash generation.

Leverage Risk

Healthy

Limited debt-to-equity data available.

Revenue Decline

Healthy

Revenue is stable or growing over recent quarters — demand appears durable.

Cash Burn

Healthy

Free cash flow is consistently positive — the business self-funds without external capital reliance.

Share Dilution

Healthy

Shares decreased 5.0% — net buybacks are reducing shares outstanding and boosting per-share value.

Metrics at a Glance

as of March 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue
$4.10B
2.9%
Q. Revenue
$1.04B
TTM EBITDA
$811.45M
10.3%
TTM Op. Income
$556.61M
4.8%
Q. Op. Income
$141.96M
TTM Net Income
$429.89M
5.0%
Q. Net Income
$112.77M
EPS
$1.58
Shares Out.
$71.42M
2.9%
$4.10B in TTM revenue grew 2.9% YoY, reaching $1.04B last quarter. TTM EBITDA of $811.45M and TTM operating income of $556.61M shows growth is flowing through. Net income of $429.89M TTM confirms the company is converting revenue into profit. Revenue is growing modestly — monitor for acceleration or deceleration.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin
70.8%
2.0%
EBITDA Margin
19.1%
Op. Margin
13.6%
1.9%
Net Margin
10.8%
13.9%
Op. margin of 13.6% is up 0.3% YoY — cost efficiency is improving. Net margin at 10.8% and gross margin of 70.8% — earnings take a bigger bite when COGS stays lean..

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio
30.7x
P/S Ratio
3.2x
P/B Ratio
3.2x
At 30.7x P/E, the stock trades at a premium — the market expects above-average growth. P/S of 3.2x and P/B of 3.2x provide additional context. The premium P/E is not backed by strong revenue growth — the stock may be overvalued.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets
$6.31B
Cash
$1.06B
Long-Term Debt
N/A
Book Value
$4.15B
D/E Ratio
N/A
Debt/EBITDA
0.0

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow
$151.04M
Free Cash Flow
$120.26M
339.1%
FCF Margin
2.9%
FCF / Net Income
1.1
FCF of $120.26M on $151.04M in operating cash flow. The FCF / Net Income ratio of 0.3x indicates partial cash conversion — earnings quality needs attention.

Related Stocks in Healthcare

View Sector
NVDA$4.57T
Nvidia
Semiconductors
GOOG$3.96T
Alphabet Inc. (Class C)
Internet Content & Information
AAPL$3.67T
Apple Inc.
Consumer Electronics
GOOGL$3.66T
Alphabet Inc. (Class A)
Internet Content & Information
MSFT$3.46T
Microsoft
Software - Infrastructure
AMZN$2.56T
Amazon
Internet Retail
META$1.66T
Meta Platforms
Internet Content & Information
AVGO$1.63T
Broadcom
Semiconductors